Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk

Next Previous
Trial Profile

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Venous thromboembolism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms MARINER
  • Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

  • 07 Apr 2022 Results of a pooled analysis (MAGELLAN and MARINER trials data) assessed that the patients with major bleeding but not those with non-major clinically relevant bleeding, would be at an increased risk of all-cause mortality published in the Circulation
  • 27 Jul 2021 Results of subgroup analysis assessing rates of efficacy and safety outcomes for rivaroxaban versus placebo in patients with 75 years of age or older with those in patients less than 75 years of age published in the Journal of Thrombosis and Haemostasis
  • 30 Jun 2020 Results published in the Journal of the American College of Cardiology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top